- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05868174
Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors
A Phase 1b Dose Escalation/Expansion Study of the Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX (CAIX)-Expressing Solid Tumors
Study Overview
Status
Intervention / Treatment
Detailed Description
Part 1 (dose escalation) will evaluate the combination of 3 different activities of 177Lu-TLX250 and 3 different dose levels of peposertib.
Patients with CAIX positive solid tumors will be enrolled in a given dose/activity level in Cohorts of approximately 2-6 patients.
Treatment cycles will have a fixed length of 84 days. Patients will be treated during 3 cycles, or until clinically significant progression or unacceptable toxicity.
Part 2 (dose expansion) patients will be enrolled in 2 Cohorts:
- Cohort A: 40 patients with metastatic or non-resectable ccRCC
- Cohort B: 20 patients with CAIX-positive solid tumors (excluding RCC).
Patients will be treated at the Recommended phase 2 dose of 177Lu-TLX250 in combination with peposertib at the dosing schedule of the selected Recommended phase 2 dose.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Medical Director, MD
Study Locations
-
-
-
Adelaide, Australia
- Recruiting
- Ashford (Icon) Cancer Centre
-
Contact:
- Principal Investigator
- Phone Number: 00
- Email: info@telixpharma.com
-
Principal Investigator:
- Dainik Patel
-
Brisbane, Australia
- Not yet recruiting
- Princess Alexandra Hospital
-
Principal Investigator:
- Kenneth O'Byrne
-
Contact:
- Principal Investigator
-
Melbourne, Australia
- Not yet recruiting
- Austin Health
-
Principal Investigator:
- Andrew Scott
-
Contact:
- Princiapl Investigator
-
Perth, Australia
- Recruiting
- GenesisCare Murdoch
-
Contact:
- Principal Investigator
- Phone Number: 0000
- Email: info@telixpharma.com
-
Principal Investigator:
- Nat Lenzo
-
-
New South Wales
-
North Ryde, New South Wales, Australia
- Not yet recruiting
- Macquarie University
-
Contact:
- Principal Investigator
-
Principal Investigator:
- Howard Gurney
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically confirmed advanced or metastatic solid tumor that has progressed on or during/after recognized standard of care therapies and are not eligible for resection, or patients that are not eligible or not consenting to recognized standard of care therapies.
- At least one measurable lesion on CT/MRI according to RECIST 1.1 with corresponding 89Zr-TLX250 uptake (i.e., CAIX positive).
- CAIX positivity in at least 75% of the total lesion volume (defined as 89Zr- TLX250 uptake with intensity significantly greater than normal liver [i.e., standardized uptake value [SUV]max at least 1.5 times SUV of normal liver]).
- ECOG status 0 or 1.
- Have adequate organ function during screening
- Must have a life expectancy of at least 6 months.
Exclusion Criteria:
- Prior 177Lu-TLX250 or other radioligand therapy; or any prior CAIX targeting therapy.
- Known hypersensitivity to compounds of similar chemical or biologic composition to peposertib, girentuximab radiolabelled by zirconium or lutetium, any excipient in the study medication or any other intravenously administered human proteins/peptides/antibodies.
- Administration of any radionuclide within 10 half-lives of the radionuclide prior to signature of the ICF.
- Patients who have had chemotherapy, definitive radiation, biological cancer therapy, or investigational agent/device within 28 days of first planned dose of study therapy.
- Patients who had > 2 prior lines of cytotoxic chemotherapy or had Grade 4 neutropenia or Grade 3/Grade 4 thrombocytopenia (both of a duration of at least 48 hours) during the last line of therapy. Note: This criterion may be removed in total or in part by the SRC upon review of the safety data from the initial dose level(s).
- Patients who cannot discontinue concomitant medications or herbal supplements that are strong inhibitors or strong inducers of cytochrome P450 (CYP) isoenzymes CYP3A4/5, CYP2C9, and CYP2C19. Concomitant use of CYP3A4/5 substrates with a narrow therapeutic index are also excluded.
- Patients who cannot discontinue concomitant H2-blockers or proton-pump inhibitors (PPIs). Patients may confer with the investigator to determine if such medications can be discontinued. These must be discontinued ≥ 5 days prior to study treatment. Patients do not need to discontinue calcium carbonate.
- Patients who are receiving therapeutic doses of anticoagulation, including but not limited to low-molecular weight heparin in therapeutic dosing or platelet aggregation inhibitors. Note: This criterion may be removed by the SRC upon review of the safety data from the initial dose level(s).
- Patients with ≥ 5 bone metastases and/or bulky (> 3cm in diameter) pelvic or femoral tumors, and/or metastases/tumor in the vertebral spine involving > 3 vertebrae.
- Any severe concomitant condition which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol, in the opinion of the investigator.
- Presence of active and uncontrolled infections or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study.
- Requirement of concurrent use of other anti-cancer treatments or agents other than study medications. Supportive care therapies are permitted.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 89Zr-TLX250, 177Lu-TLX250 and Peposertib
Diagnostic test: A single IV administration of 37 Megabecquerel (+/- 10%) 89Zr-DFO-girentuximab, containing a mass dose of 10 mg of girentuximab, followed by a diagnostic scan Treatment test: A single IV administration that could be 1887 - 2516 or 3145 Megabecquerel (+/- 10%) 177Lu-DOTA-girentuximab,containing a mass dose of 10 mg of girentuximab, on Day 1 of each 84-day cycle and p.o. administration of that could be 100-150 or 200 mg Peposertib BID on days 4-21 of each 84-day cycle. |
Single IV administration followed by 89Zr-DFO-girentuximab PET/CT (or PET/MRI) scan at screening and approximately 8-10 weeks (±1 week) after Cycle 3 Day 1, as well as at the end of treatment visit (if feasible).
The PET/CT should be obtained within 4-7 days after 89Zr-TLX250 administration
Other Names:
Dose escalation and de-escalation for the determination of the Maximum tolerated combination/ Recommended phase 2 dose. All subjects will receive 177Lu-TLX250 intravenously on day 1 and Peposertib BID on days 4-21 of each 84-day cycle.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety parameter Dose Limited Toxicity (DLT)
Time Frame: 42 days
|
Dose level toxicity evaluation using Partial Ordering Bayesian Logistic Regression Model Method (PO-BLRM)
|
42 days
|
Safety parameter Laboratory Examinations
Time Frame: 42 days
|
Frequency of occurrence and severity of abnormal findings in safety investigations regarding Laboratory examinations
|
42 days
|
Safety parameter Vital signs
Time Frame: 42 days
|
Frequency of occurrence and severity of abnormal findings in safety investigations regarding the vital signs
|
42 days
|
Safety parameter ECG
Time Frame: 42 days
|
Frequency of occurrence and severity of abnormal findings in the 12-lead ECG (ECG QT interval)
|
42 days
|
Safety parameter Adverse Events and Treatment-Related Adverse Events
Time Frame: 42 days
|
Assessment of AEs graded by the Common Terminology Criteria for Adverse Events (CTCAE) Criteria, Version 5.0
|
42 days
|
Disease impact causing changes in Eastern Cooperative Oncology Group (ECOG) Performance scale.
Time Frame: Screening/Baseline, Day1, Day 29, D57 and End of Treatment
|
Quality of life ( in terms of their ability to care for themself, daily activity, and physical ability (walking, working) is to be evaluated using the ECOG Performance Scale.
|
Screening/Baseline, Day1, Day 29, D57 and End of Treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival (OS)
Time Frame: Every 3 months ± 2 weeks for 24 months after the last 177Lu-TLX250 administration
|
Overall Survival (OS), determined from enrollment , until death from any cause
|
Every 3 months ± 2 weeks for 24 months after the last 177Lu-TLX250 administration
|
Tumor objective response rate (ORR)
Time Frame: Every 3 months ± 2 weeks for 12 months after the last 177Lu-TLX250 administration
|
Tumor response in terms of objective response rate (ORR) (solid tumor tissue response and overall radiological response [tumor response by RECIST 1.1 and overall radiological response by RECIST 1.1])
|
Every 3 months ± 2 weeks for 12 months after the last 177Lu-TLX250 administration
|
Progression-free survival (PFS)
Time Frame: Every 3 months ± 2 weeks for 12 months after the last 177Lu-TLX250 administration
|
Progression free survival (PFS) defined as the time from enrollment to disease progression confirmed by radiology, clinical progression or death (whichever comes first)
|
Every 3 months ± 2 weeks for 12 months after the last 177Lu-TLX250 administration
|
Immunogenicity by formation of ADA(HACA) in blood
Time Frame: 84 days
|
This outcome will be measured by analyzing the incidence of ADA(HACA) formation in blood on day 1, day 22, Day 43, Day 57 of each cycle (each cycle is 84 days) and at the end of treatment visit.
|
84 days
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Kidney Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Neoplasms
- Carcinoma, Renal Cell
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- Peposertib
Other Study ID Numbers
- 177Lu-TLX250-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumor
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia, China
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Pyxis Oncology, IncRecruiting
-
Neurogene Inc.Merck Sharp & Dohme LLCActive, not recruitingSolid Tumor | Advanced Solid TumorUnited States, Australia, Canada
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedSolid Tumor | Advanced Solid TumorSpain, United States, Netherlands, United Kingdom
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesChina
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesUnited States
-
Jazz PharmaceuticalsMerck Sharp & Dohme LLCRecruitingAdvanced Solid Tumor | Metastatic Solid TumorUnited States
-
PharmaEngineNot yet recruitingAdvanced Solid Tumor | Metastatic Solid Tumor
Clinical Trials on 89Zr-TLX250
-
Telix International Pty LtdCompletedClear Cell Renal Cell CarcinomaUnited Kingdom, United States, Australia, Turkey, Netherlands, Belgium, Canada, France
-
Telix International Pty LtdCompletedCarcinoma, Renal Cell | Clear Cell Renal Cell CarcinomaJapan
-
Telix International Pty LtdGrand Pharmaceutical (China) Co., Ltd.CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Cancer | Suspected Recurrent Renal Clear Cell CarcinomaChina
-
Institut Cancerologie de l'OuestATONCOCompleted
-
Institut Cancerologie de l'OuestTelix Pharmaceutical; SIRIC ILIADRecruiting
-
Affiliated Hospital of Jiangnan UniversityRecruiting
-
Wuxi No. 4 People's HospitalNot yet recruitingSolid Tumor, AdultChina
-
South Metropolitan Health ServiceTelix Pharmaceuticals (Innovations) Pty LimitedCompletedUrothelial CarcinomaAustralia
-
Wuxi No. 4 People's HospitalUnknownSolid Tumor, AdultChina
-
Radboud University Medical CenterABX CRO; Telix International Pty LtdCompleted